UNIQUELY CHEAP GENMAB (BUY, 33% UPSIDE)
12/07/18 -"Punters made a killing in Europe’s largest independent biotech, Genmab (Buy, Denmark), during January 2015–June 2017 – the scrip quadrupled, banking on the multi-blockbuster potential of its blood ..."
Pages
49
Language
English
Published on
12/07/18
You may also be interested by these reports :
25/03/24
Perfect execution of capacity ramp-up key for meeting targets – TP increased to CHF 81 (from CHF 75) – Reduce reiterated
21/03/24
BioNTech reported weaker than expected FY23 sales figures (-17.7%), explained by the structure of the partnering deal with Pfizer. However, investors ...
20/03/24
FDA approves TRYVIO (aprocitentan) for hypertension
19/03/24
Family controlled UCB (ADD; Belgium) has been one of the strongest performing pharma stocks (+36% in the share price) in 2024. While the recent surge ...